Both GM and Honda have more than 1,200 fuel cell patents between them, filed between 2002 and 2012, and experimental vehicle fleets. They are the top two companies in terms of total fuel cell patents according to the Clean Energy Patent Growth Index.
Both companies aim to develop the vehicles by 2020. The alliance will bring down their costs in building this expensive technology by sharing each other�� expertise and suppliers.
Why Fuel Cell Vehicles?
The U.S. mandate requires corporate average fuel economy of 54.5 miles per gallon by 2020 and there is no better competent than fuel cell vehicles. Why? Fuel cells have highly fuel-efficient technology compared to gasoline and electric batteries. Secondly, it has a longer driving range (up to 400 miles) than electric cars but pollutes less than gasoline vehicles.
5 Best European Stocks To Invest In Right Now: Mercury General Corporation (MCY)
Mercury General Corporation, together with its subsidiaries, engages in writing personal automobile insurance products. The company also writes homeowners, commercial automobile and property, mechanical breakdown, fire, and umbrella insurance products. Its insurance products cover collision, property damage liability, bodily injury liability, comprehensive, personal injury protection, underinsured and uninsured motorist, and other hazards for automobile policy holders. The company sells its policies through a network of independent agents in California, Florida, Georgia, Illinois, Texas, Oklahoma, New York, New Jersey, Virginia, Pennsylvania, Arizona, Nevada, and Michigan. Mercury General Corporation was founded in 1960 and is headquartered in Los Angeles, California.
Advisors' Opinion:- [By Chuck Carnevale] their website:
��ercury General (NYSE-MCY) is the leading independent broker and agency writer of automobile insurance in California and has been one of the fastest growing automobile insurers in the nation. It is ranked as the third largest private passenger automobile insurer in California, with total assets over $4 billion. Mercury also writes automobile insurance in Arizona, Florida, Georgia, Illinois, Michigan, Nevada, New Jersey, New York, Oklahoma, Pennsylvania, Texas and Virginia. In addition to automobile insurance, Mercury writes other lines of insurance in various states, including mechanical breakdown and homeowners insurance.��/p>
[ Enlarge Image ]
Performance and Dividends Impacted by Operating Stress
It should be clear from the above graphs that the earnings records of these three Dividend Champions have been far from steady, consistent or reliable. Therefore, I cannot get comfortable either recommending them or investing in them because I cannot get comfortable predicting what their future operating results may be. Furthermore, by examining the performance results associated with the above earnings and price-correlated graphs illustrates a lot of uncertainty. A focus on the earnings growth rate column illustrates a lot of stress on each company�� ability to keep their dividend streaks alive (Blue Circles).
[ Enlarge Image ]
[ Enlarge Image ]
[ Enlarge Image ]
The Overvaluation Rejection
Other reasons besides irregular earnings growth that caused a Dividend Champion to be rejected include one of my all-time favorites, valuation. Or to be more precise ��overvaluation. The following example, McCormick & Co. (MKC), represents one of my favorite Dividend Champions based on a very consistent above-average record of earnings growth that produced its impressive dividend streak. The only reason that this Dividend Champion was rejected was because of current overvaluation.
[ Enlarge Imag
Top Clean Energy Companies To Own For 2014: Body Central Corp.(BODY)
Body Central Corp. operates as a specialty retailer of young women's apparel and accessories in the south, mid-Atlantic, and midwest regions of the United States. The company operates specialty apparel stores under the Body Central and Body Shop banners, as well as a direct business of its Body Central catalog and e-commerce Website at bodyc.com. Its stores feature an assortment of tops, dresses, bottoms, jewelry, accessories, and shoes under Body Central and Lipstick labels. As of March 8, 2012 it operated 241 specialty apparel stores in 24 states. The company, formerly known as Body Central Acquisition Corp., was founded in 1972 and is headquartered in Jacksonville, Florida.
Advisors' Opinion:- [By Roberto Pedone]
Body Central (BODY) operates apparel stores and also conducts direct business via catalogues and Web site. This stock closed up 3.8% to $3.52 in Tuesday's trading session.
Tuesday's Range: $3.40-$3.55
52-Week Range: $3.09-$13.39
Tuesday's Volume: 475,000
Three-Month Average Volume: 421,188From a technical perspective, BODY trended higher here right above some near-term support at $3.21 with above-average volume. This move pushed shares of BODY into breakout territory, since the stock took out some near-term overhead resistance at $3.50. This move is also coming off oversold territory, since BODY's current relative strength index reading is 29.89. Oversold can always get more oversold, but it's also an area where a stock can experience a powerful bounce from.
Traders should now look for long-biased trades in BODY as long as it's trending above some key near-term support levels at $3.21 or at $3.09 and then once it sustains a move or close above Tuesday's high of $3.55 with volume that hits near or above 421,188 shares. If we get that move soon, then BODY will set up to re-test or possibly take out its next major overhead resistance levels at $4 to $4.50.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Body Central (Nasdaq: BODY ) , whose recent revenue and earnings are plotted below. - [By Sally Jones]
A high number of billionaire investors hold today�� featured apparel companies including American Eagle Outfitters (AEO), Urban Outfitters (URBN) and Body Central Corp. (BODY), as revealed by the GuruFocus 52-week low screener.
Top Clean Energy Companies To Own For 2014: Bellicum Pharmaceuticals Inc (BLCM)
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company�� product pipeline includes clinical product candidates, such as BPX-501, which is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation; BPX-201, which is a dendritic cell cancer vaccine; and Preclinical product candidates, including BPX-701, which is a T cell receptor (TCR) product candidate for solid tumors; BPX-401, which is a CAR-T product candidate for hematological cancers that express the CD19 antigen, and BPX-601, which is a TCR product candidate for solid tumors expressing the preferentially-expressed antigen in melanoma (PRAME). The Company�� Chemical Induction of Dimerization (CID) technology platform engineers and controls components of the immune system in real time.
CaspaCIDe
CaspaCIDe is the Company�� Chemical Induction of Dimerization (CID) safety switch technology. The CaspaCIDe eliminates cells in the event of toxicity. The CaspaCIDe switch consists of the CID-binding domain coupled to the signaling domain of caspase-9 (iCasp9), an enzyme that is part of the apoptotic pathway. The infusion of rimiducid triggers activation of this domain of caspase-9, which in turn leads to selective apoptosis of the CaspaCIDe-containing cells. The CaspaCIDe technology is applied to its lead clinical product candidate, BPX-501 and to its TCR product candidate, BPX-701.
The CaspaCIDe technology has demonstrated clinical efficacy in human patients beginning as soon as 30 minutes after administration of the activating drug, rimiducid. In the preclinical studies, rimiducid reduced or eliminated CaspaCIDe-containing cells in a dosage dependent manner. The National Cancer Institute is conducting a Phase I/II clinical trial for sarcoma! and other solid tumors with a chimeric antigen receptor (CAR) construct targeting a solid tumor antigen combined with CaspaCIDe.
CIDeCAR
CIDeCAR Technology consists of a CAR T cell that incorporates its co-stimulatory domain, MC, for improved T-cell activation and proliferation, and the CaspaCIDe safety switch. CAR interaction with cancer cell antigens leads to MC signaling, which then leads to activation of T cells. In the event of serious toxicity, rimiducid activation of caspase-9 eliminates the CIDeCAR T cells.
The Company has conducted proof-of-principle preclinical studies for CIDeCAR technology, CIDeCAR candidate BPX-401 and CIDeCAR solid tumor CAR targeting Her2, in which, both were evaluated in vitro. These preclinical studies demonstrated that CIDeCAR technology results in enhanced activation, proliferation and tumor cell killing; and the elimination of these CIDeCAR T cells after exposure to rimiducid.
GoCAR-T
The Company�� GoCAR-T technology incorporates a switch that activates CAR T cells when triggered by both rimiducid and the targeted antigen expressed on the surface of the cancer cells. The GoCAR-T technology separates the CIDeCAR dual co-stimulatory domain, MC, from the antigen recognition domain and moves it onto a separate molecular switch that can be controlled by rimiducid. GoCAR-T cells can only be fully activated when exposed to both the cancer cells and rimiducid. This separation controls the degree of activation of the CAR T cells through adjustments to the amount of rimiducid administered, but still in a tumor-dependent manner.
The Company conducted a proof-of-principle in vitro study for GoCAR-T technology, in which it demonstrated that the GoCAR-T cells targeting the PSCA antigen can only be fully activated, as evidenced by production of IL-2 (left panel) and T-cell proliferation (right panel) when the GoCAR-T cells are exposed to both their target PSCA-expressing human pancreatic cancer cells ! and rimid! ucid. In further in vivo studies of GoCAR-T technology, target antigen PSCA-expressing Capan-1 human pancreatic tumors were established in immune-deficient, or NSG, mice. After seven days, five mice received control T cells modified only with firefly luciferase, an imaging protein, and 10 mice received T cells modified with MC in the form of a molecular switch or iMC, plus a PSCA. CAR (together, BPX-601) and firefly luciferase. Five mice in this second group also received 5 mg/kg rimiducid weekly. T-cell imaging clearly demonstrated that GoCAR-T cells can be stimulated to proliferate in vivo when exposed to target antigen-expressing cancer cells by rimiducid administration.
DeCIDe
The DeCIDe technology is used to control the activation of dendritic cells. The DeCIDe technology couples the signaling domains of CD40 and MyD88 to its CID binding domain, to create inducible MC switch, which is then insert into dendritic cells along with the PSMA antigen to take control of the activation of the dendritic cells and the resulting immune response to cancer. Upon exposure to rimiducid, DeCIDe-containing dendritic cells become highly activated. The DeCIDe technology activates dendritic cells with rimiducid after the patient has been vaccinated and the dendritic cells have migrated to the draining lymph nodes.
The cultured BPX-201 cells transduced with DeCIDe switch technology produce supra-normal levels of IL-12 in response to rimiducid. These data demonstrates that, in addition to the temporal control of dendritic cell activation that DeCIDe technology affords, once exposed to rimiducid, DeCIDe-containing dendritic cells become highly activated, which may lead to more potent anti-cancer activity in patients.
BPX-501
The Company�� CaspaCIDe product candidate BPX-501, is under development for the treatment of hematological diseases. BPX-501 is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation (HSCT), us! ing donor! stem cells. The BPX-501 eliminates donor T cells through the triggering of the CaspaCIDe safety switch upon emergence of Graft-versus-host disease (GvHD). The BPX-501 improves stem cell engraftment and accelerates immune system recovery, while providing for resolution of GvHD. The BPX-501 has a range of applications: an add-back of donor T cells administered to accelerate immune system recovery after allogeneic haplo-HSCT in which the T cells in the transplanted stem cells were depleted, and a donor T-cell infusion administered to prevent or treat relapse of underlying disease after allogeneic HSCT independent of donor match.
The product has undergone a 10-patient Phase I clinical trial with CaspaCIDe modified T cells. Four patients developed GvHD after donor T-cell infusion. A single dosage of rimiducid eliminated around 90% of the modified T cells and resolved GvHD in all four patients without recurrence of GvHD. In the second clinical trial of CaspaCIDe-modified T cells, these demonstrations have been replicated in preliminary data from three patients. BPX-501 is being evaluated in multiple Phase I/II clinical trials in the United States, which includes BP-001, a clinical trial in adults and and BP-003, a clinical trial in children. During the BP-001 clinical trial, BPX-501 is administered after initial allogeneic HSCT for hematological cancers. The BP-003 clinical trial in children with orphan inherited blood disorders includes the administration of BPX-501 after initial allogeneic HSCT. The Company also initiated an additional Phase I/II clinical trial, BPX-004 in children with hematological cancers or orphan inherited blood disorders.
BPX-201
The Company�� product candidate under development, BPX-201 is a dendritic cell cancer vaccine intended to treat metastatic castrate-resistant prostate cancer (mCRPC). BPX-201 is an autologous therapy, in which the patient�� own white blood cells are extracted and modified ex vivo. The cells are matured and then gen! etically ! engineered to express the DeCIDe switch domains and the prostate-specific membrane antigen (PSMA) antigen. The modified cells are then washed, apportioned into individual dosages, and frozen for later administration to the patient. The incorporation of the DeCIDe switch in the presence of rimiducid activates the therapy.
The Company is evaluating BPX-201 in an 18-patient Phase I clinical trial for mCRPC. It is evaluating opportunities for BPX-201 in combination with other cancer immunotherapies, such as checkpoint inhibitors.
BPX-701
The Company�� CaspaCIDe T cell receptor (TCR) Product Candidate, BPX-701 is under development for the treatment of Solid Tumors. BPX-701 is a TCR-based therapy for the treatment of PRAME-expressing melanoma, sarcomas and neuroblastomas. BPX-701 is designed to target preferentially-expressed antigen in melanoma (PRAMEa gene) that is predominantly expressed in human melanomas but not in normal tissues.
The BPX-701 has demonstrated complete elimination in response to rimiducid. The Clinical Cancer Research 2011 has demonstrated that PRAME-specific clones showed high reactivity against a panel of PRAME positive tumor cell lines, metastatic melanoma, sarcomas and neuroblastoma tissues, and no reactivity against normal cell types, with the exception of low reactivity against kidney epithelial cells and intermediate reactivity against mature dendritic cells. The vitro studies demonstrated BPX-701�� affinity to panels of cancer cells presenting PRAME peptides and low affinity to non-tumor cells. In other in vitro studies, rimiducid administration has proved the ability to eliminate BPX-701 cells.
BPX-401
The Company�� CIDeCAR Product Candidate under development, BPX-401, is developed for the treatment of Hematological Cancers, such as acute lymphotcytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and certain types of non-Hodgkin�� lymphoma. The CIDeCAR consists of CAR T cells modified to! include ! its CaspaCIDe safety switch and in which the CAR incorporates the signaling domains of two proteins, MyD88 and CD40. These proteins form the Company�� dual co-stimulatory domain, MC, which is designed to activate T cells in the presence of cancer cells. The Company has generated preclinical proof-of-principle data in vitro signifying that BPX-401 has CAR T cell activation and proliferation potential, and may be effective in killing cancer cells.
BPX-601
The Company�� GoCAR-T Product Candidate, BPX-601, is proposed for the treatment of Solid Tumors. The BPX-601 is undergoing preclinical studies for the treatment of solid tumors overexpressing the prostate stem cell antigen (PSCA), such as some prostate, pancreatic, bladder, esophageal and gastric cancers. The Company�� GoCAR-T technology consists of CAR and T cells. GoCAR-T controls activation and proliferation of the CAR T cells through the scheduled administration of a course of rimiducid infusions.
BPX-601 is undergoing preclinical studies for the treatment of solid tumors overexpressing the PSCA antigen. The Company has demonstrated positive proof-of-principle data in an animal pancreatic tumor model.
The Company competes with Adaptimmune Limited, bluebird bio, Inc., Celgene Corporation, Cellectis SA, GlaxoSmithKline plc, Intrexon Corporation, Juno Therapeutics, Inc., Kite Pharma, Inc., Novartis AG and Pfizer Inc.
Advisors' Opinion:- [By John Udovich]
Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) ��meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.
Top Clean Energy Companies To Own For 2014: The York Water Company(YORW)
The York Water Company engages in impounding, purifying, and distributing drinking water in Pennsylvania. It has two reservoirs, Lake Williams and Lake Redman, which together holds up to approximately 2.2 billion gallons of water. The company also has a 15-mile pipeline from the Susquehanna River to Lake Redman that provides access to an additional supply of 12.0 million gallons of water per day. As of December 31, 2010, it served 182,000 residential, commercial, industrial, and other customers in 39 municipalities in York County and 7 municipalities in Adams County. The company was founded in 1816 and is based in York, Pennsylvania.
Advisors' Opinion:- [By David Dittman]
Question: I like the H2O business. I��e owned American Water Works Co Inc (NYSE: AWK) for eons. Is there any compelling reason to own more than one water utility? At what point does is there no marginal benefit added? I do like Connecticut Water Service Inc (NSDQ: CTWS) and York Water Co (NSDQ: YORW) as slow, consistent growers.
As Ben Franklin said, ��ittle strokes fell great oaks.��/p>
No comments:
Post a Comment